US 11,873,492 B2
Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof
Fangfang Tao, Zhejiang (CN); Zhiqian Zhang, Zhejiang (CN); Wenhong Liu, Zhejiang (CN); Ye Xu, Zhejiang (CN); Qingling Liu, Zhejiang (CN); and Junfeng Li, Zhejiang (CN)
Assigned to Zhejiang Chinese Medical University, Zhejiang (CN)
Filed by Zhejiang Chinese Medical University, Zhejiang (CN)
Filed on Jun. 29, 2022, as Appl. No. 17/852,380.
Claims priority of application No. 202111494647.0 (CN), filed on Dec. 8, 2021.
Prior Publication US 2023/0174986 A1, Jun. 8, 2023
Int. Cl. C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61P 35/04 (2006.01); C12N 15/86 (2006.01)
CPC C12N 15/1135 (2013.01) [A61P 35/04 (2018.01); C12N 15/86 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2740/15043 (2013.01)] 3 Claims
 
1. A medication for inhibiting metastasis and invasion of breast cancer, comprising shRNAs for inhibiting expression of human LINC01614, wherein the shRNAs for inhibiting expression of human LINC01614 comprises a shRNA-1 and/or a shRNA-2, a sense strand nucleotide sequence of the shRNA-1 is shown as SEQ ID No. 3, an antisense strand nucleotide sequence of the shRNA-1 is shown as SEQ ID No. 4, a sense strand nucleotide sequence of the shRNA-2 is shown as SEQ ID No. 5, and an antisense strand nucleotide sequence of the shRNA-2 is shown as SEQ ID No. 6.